Comprehensive genomic profiling enables the detection of genomic biomarkers in
advanced solid tumors. However, efficient patient screening for the success of precision …

Simple Summary The survival of patients with metastatic colorectal cancer (mCRC) has
been improved over the years and now reaches 30–40 months. However, few therapeutic …

Studies have reported the effects of the gut microbiota on colorectal cancer (CRC)
chemotherapy, but few studies have investigated the association between gut microbiota …

Purpose To evaluate a prognostic and predictive value of HER2 amplification in patients
with metastatic colorectal cancer (mCRC). Patients and Methods Patients with mCRC who …

Simple Summary Despite recent progress in the treatment of metastatic colorectal cancer
patients, novel therapeutic approaches are highly warranted to further improve outcome …

Since bevacizumab was first approved by the US Food and Drug Administration as an anti-
angiogenic therapy in 2004, angiogenesis-targeted therapy has been developed for various …

Background Second-line treatment with ramucirumab+ FOLFIRI improved overall survival
(OS) versus placebo+ FOLFIRI for patients with metastatic colorectal carcinoma …

PURPOSE Several uncommon genomic alterations beyond RAS and BRAFV600E
mutations drive primary resistance to anti–epidermal growth factor receptor (EGFR) …

ERBB2 amplification is a driver oncogenic alteration in many cancers and it has recently
been incorporated among therapeutically actionable biomarkers also in metastatic …

Background Immune checkpoint inhibitors yielded unprecedented outcomes in patients with
mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal …